imatinib mesylate has been researched along with Focal Segmental Glomerulosclerosis in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Himuro, N; Ito, K; Masutani, K; Miyake, K; Morita, N; Nakayama, T; Nawata, A; Ozaki, T; Sasaki, H; Takahashi, K; Uesugi, N; Watanabe, M; Yasuno, T; Yokota, S | 1 |
| Li, J; Luo, Y; Wang, G; Zhuo, N | 1 |
2 other study(ies) available for imatinib mesylate and Focal Segmental Glomerulosclerosis
| Article | Year |
|---|---|
Focal segmental glomerulosclerosis and concurrent glomerular microangiopathy after long-term imatinib administration.
Topics: Aged; Endothelial Cells; Female; Glomerulosclerosis, Focal Segmental; Humans; Imatinib Mesylate; Kidney Diseases; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Proteinuria | 2022 |
Imatinib-induced podocytopathies in a patient with gastrointestinal stromal tumor.
Topics: Antineoplastic Agents; Gastrointestinal Stromal Tumors; Glomerulosclerosis, Focal Segmental; Humans; Imatinib Mesylate; Kidney Function Tests; Male; Middle Aged; Nephrosis, Lipoid | 2021 |